[Effect of continuous intra-arterial infusion therapy with BLM-MMC-lentinan (B-M-L) in treating patients with hepatic metastases of esophageal cancer].
D000368:Aged; D001761:Bleomycin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D007912:Lentinan / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage*; D011134:Polysaccharides / Q000008:administration & dosage*
D008937:Mitomycins; D011134:Polysaccharides; D001761:Bleomycin; D007912:Lentinan; D016685:Mitomycin